In the current study, targeted inhibiting EML4-ALK fusion protein in NSCLC cells showed downstream suppression of pERK1/2 and reduction of cFOS, a subunit of AP-1, accompanied by downregulation of TF. This evidence concerns the gene ALK and non-small cell lung carcinoma.